Emergent Biosolutions
EBS
277 hedge funds and large institutions have $2.22B invested in Emergent Biosolutions in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 110 increasing their positions, 96 reducing their positions, and 33 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 96
2% more call options, than puts
Call options by funds: $5.88M | Put options by funds: $5.79M
0.62% less ownership
Funds ownership: 83.52% → 82.91% (-0.62%)
4% less funds holding
Funds holding: 290 → 277 (-13)
21% less capital invested
Capital invested by funds: $2.8B → $2.22B (-$580M)
30% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$21.2M |
| 2 |
GACM
Global Alpha Capital Management
Montreal,
Quebec, Canada
|
+$20.6M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$19.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$16.5M |
| 5 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$9.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$47.2M |
| 2 |
Two Sigma Investments
New York
|
-$25.6M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$18.8M |
| 4 |
Two Sigma Advisers
New York
|
-$15.1M |
| 5 |
Morgan Stanley
New York
|
-$10.1M |
EBS Hedge Fund Activity: Q3 2021 in Review
277 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q3 2021, worth a combined $2.22B — down 21% from $2.8B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of EBS and 23 opened new positions — a net loss of 10 holders — while 96 trimmed existing stakes and 110 added.
The largest buyer was Bank of America, adding an estimated $21.2M. The largest seller was Janus Henderson Group, cutting an estimated $47.2M.
- 277 institutional investors held Emergent Biosolutions (EBS) as of Q3 2021, down from 290 in Q2 2021.
- Funds reported $2.22B of Emergent Biosolutions stock for Q3 2021, down 21% quarter-over-quarter.
- 23 funds opened new Emergent Biosolutions positions in Q3 2021 and 33 closed out, a net change of -10 holders.
- The largest Emergent Biosolutions buyer in Q3 2021 was Bank of America, an estimated $21.2M added.
- The largest Emergent Biosolutions seller in Q3 2021 was Janus Henderson Group, an estimated $47.2M sold.
Based on aggregated 13F filings for Q3 2021.